{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:29:01Z","timestamp":1794320941009,"version":"4.9.0"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science, KAKENHI","doi-asserted-by":"publisher","award":["17K09869"],"award-info":[{"award-number":["17K09869"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science, KAKENHI","doi-asserted-by":"publisher","award":["15K09418"],"award-info":[{"award-number":["15K09418"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science, KAKENHI","doi-asserted-by":"publisher","award":["26460346"],"award-info":[{"award-number":["26460346"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science, KAKENHI","doi-asserted-by":"publisher","award":["18K14958"],"award-info":[{"award-number":["18K14958"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,5,30]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Thromboembolic ischemic stroke, which is mainly caused by hypertension, as well as plasma dyslipidemia, arterial fibrillation and diabetes, is a leading cause of death in the US and other countries. Numerous clinical trials for thrombolytic drugs, which aimed to pharmacologically dissolve thrombi, were conducted in the 1950s, when the first thrombolytic therapy was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In this study, we summarize the pathophysiologic features of ischemic stroke, and the history of thrombolytic therapy, and discuss the recent progress that has been made in the ongoing development of thrombolytic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190319115018","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T11:40:37Z","timestamp":1553082037000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future"],"prefix":"10.2174","volume":"25","author":[{"given":"Keita","family":"Shibata","sequence":"first","affiliation":[{"name":"Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Showa University School of Medicine, Shinagawaku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Showa University School of Medicine, Shinagawaku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nobe","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1538-7836.2005.01415.x","volume":"3","author":"Heit J.A.","year":"2005","unstructured":"Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors.","journal-title":"J Thromb Haemost"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1160\/TH17-02-0134","volume":"117","author":"Lee L.H.","year":"2017","unstructured":"Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of venous thromboembolism in Asian populations: A systematic review.","journal-title":"Thromb Haemost"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"Heit J.A.","year":"2016","unstructured":"Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism.","journal-title":"J Thromb Thrombolysis"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"","year":"2016","unstructured":". Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015.","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","volume":"369","author":"Murray C.J.","year":"2013","unstructured":"Murray CJ, Lopez AD. Measuring the global burden of disease.","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1254\/fpj.151.9","volume":"151","author":"Shichita T.","year":"2018","unstructured":"Shichita T. Molecular and cellular mechanisms underlying the sterile inflammation after ischemic stroke.","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.STR.21.4.637","volume":"21","author":"","year":"1990","unstructured":". Special report from the national institute of neurological disorders and stroke. Classification of cerebrovascular diseases III.","journal-title":"Stroke"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-006-0009-9","volume":"8","author":"Murtagh B.","year":"2006","unstructured":"Murtagh B, Smalling RW. Cardioembolic stroke.","journal-title":"Curr Atheroscler Rep"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/157340312801215791","volume":"8","author":"Arboix A.","year":"2012","unstructured":"Arboix A, Ali\u00f3 J. Acute cardioembolic cerebral infarction: Answers to clinical questions.","journal-title":"Curr Cardiol Rev"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/01.STR.23.4.486","volume":"23","author":"Timsit S.G.","year":"1992","unstructured":"Timsit SG, Sacco RL, Mohr JP. Early clinical differentiation of cerebral infarction from severe atherosclerotic stenosis and cardioembolism.","journal-title":"Stroke"},{"key":"ref=11","first-page":"32","volume":"44","author":"Lund R.W.","year":"2014","unstructured":"Lund RW. Lacunar infarction, mortality over time and mortality relative to other ischemic strokes.","journal-title":"J Insur Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e318245fac5","volume":"125","author":"Roger V.L.","year":"2012","unstructured":"Roger VL, Go AS, Lloyd-Jones DM. Heart disease and stroke statistics--2012 update: A report from the American Heart Association.","journal-title":"Circulation"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10641960600549082","volume":"28","author":"Lastilla M.","year":"2006","unstructured":"Lastilla M. Lacunar infarct.","journal-title":"Clin Exp Hypertens"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000210457.89798.0e","volume":"66","author":"Sacco S.","year":"2006","unstructured":"Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A population-based study of the incidence and prognosis of lacunar stroke.","journal-title":"Neurology"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.STR.22.2.175","volume":"22","author":"Chamorro A.","year":"1991","unstructured":"Chamorro A, Sacco RL, Mohr JP. Clinical-computed tomographic correlations of lacunar infarction in the Stroke Data Bank.","journal-title":"Stroke"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.STR.30.12.2513","volume":"30","author":"Petty G.W.","year":"1999","unstructured":"Petty GW, Brown RD, Whisnant JP, Sicks JD, O\u2019Fallon WM, Wiebers DO. Ischemic stroke subtypes: A population-based study of incidence and risk factors.","journal-title":"Stroke"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(13)70060-7","volume":"12","author":"Wardlaw J.M.","year":"2013","unstructured":"Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging.","journal-title":"Lancet Neurol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00702-004-0192-1","volume":"111","author":"Peralta C.","year":"2004","unstructured":"Peralta C, Werner P, Holl B. Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.45.6.1161","volume":"45","author":"Yoshitake T.","year":"1995","unstructured":"Yoshitake T, Kiyohara Y, Kato I. Incidence and risk factors of vascular dementia and Alzheimer\u2019s disease in a defined elderly Japanese population: the Hisayama Study.","journal-title":"Neurology"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1161\/01.STR.31.11.2616","volume":"31","author":"Tanizaki Y.","year":"2000","unstructured":"Tanizaki Y, Kiyohara Y, Kato I. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study.","journal-title":"Stroke"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/01.STR.13.1.62","volume":"13","author":"Tanaka H.","year":"1982","unstructured":"Tanaka H, Ueda Y, Hayashi M. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community.","journal-title":"Stroke"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/dmrr.490","volume":"20","author":"Mankovsky B.N.","year":"2004","unstructured":"Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus.","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.1987.03390070069025","volume":"257","author":"Abbott R.D.","year":"1987","unstructured":"Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. The Honolulu Heart Program.","journal-title":"JAMA"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000135654","volume":"26","author":"Shinohara Y.","year":"2008","unstructured":"Shinohara Y, Gotoh F, Tohgi H. Antiplatelet cilostazol is beneficial in diabetic and\/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.","journal-title":"Cerebrovasc Dis"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"Dormandy J.A.","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial.","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bmj.309.6946.11","volume":"309","author":"Lindenstr\u00f8m E.","year":"1994","unstructured":"Lindenstr\u00f8m E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study.","journal-title":"BMJ"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","volume":"320","author":"Iso H.","year":"1989","unstructured":"Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.","journal-title":"N Engl J Med"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"Amarenco P.","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A. High-dose atorvastatin after stroke or transient ischemic attack.","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"Amarenco P.","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.","journal-title":"Lancet Neurol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/STROKEAHA.107.488791","volume":"39","author":"Vergouwen M.D.","year":"2008","unstructured":"Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease.","journal-title":"Stroke"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"Wolf P.A.","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.","journal-title":"Stroke"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"Hart R.G.","year":"1999","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis.","journal-title":"Ann Intern Med"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"Patel M.R.","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/bmj.303.6803.605","volume":"303","author":"Qizilbash N.","year":"1991","unstructured":"Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes.","journal-title":"BMJ"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","volume":"258","author":"Kannel W.B.","year":"1987","unstructured":"Kannel WB, Wolf PA, Castelli WP, D\u2019Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study.","journal-title":"JAMA"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archneur.1990.00530060107027","volume":"47","author":"Love B.B.","year":"1990","unstructured":"Love BB, Biller J, Jones MP, Adams HP, Bruno A. Cigarette smoking. A risk factor for cerebral infarction in young adults.","journal-title":"Arch Neurol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/01.STR.0000124459.33597.00","volume":"35","author":"Iso H.","year":"2004","unstructured":"Iso H, Baba S, Mannami T. Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I.","journal-title":"Stroke"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuron.2010.07.002","volume":"67","author":"Moskowitz M.A.","year":"2010","unstructured":"Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments.","journal-title":"Neuron"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000049119","volume":"11","author":"Baron J.C.","year":"2001","unstructured":"Baron JC. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications.","journal-title":"Cerebrovasc Dis"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00001756-199306000-00027","volume":"4","author":"Mies G.","year":"1993","unstructured":"Mies G, Iijima T, Hossmann KA. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat.","journal-title":"Neuroreport"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm1735","volume":"14","author":"Lo E.H.","year":"2008","unstructured":"Lo EH. A new penumbra: transitioning from injury into repair after stroke.","journal-title":"Nat Med"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1152\/physrev.1999.79.4.1431","volume":"79","author":"Lipton P.","year":"1999","unstructured":"Lipton P. Ischemic cell death in brain neurons.","journal-title":"Physiol Rev"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainresrev.2006.11.003","volume":"54","author":"Mehta S.L.","year":"2007","unstructured":"Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics.","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ceca.2010.01.003","volume":"47","author":"Szydlowska K.","year":"2010","unstructured":"Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity.","journal-title":"Cell Calcium"},{"key":"ref=45"},{"key":"ref=46"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"II128","DOI":"10.1177\/15266028040110S614","volume":"11","author":"Ouriel K.","year":"2004","unstructured":"Ouriel K. A history of thrombolytic therapy.","journal-title":"J Endovasc Ther"},{"key":"ref=48","first-page":"318","volume":"34","author":"Sikri N.","year":"2007","unstructured":"Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction.","journal-title":"Tex Heart Inst J"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1172\/JCI103071","volume":"34","author":"Tillett W.S.","year":"1955","unstructured":"Tillett WS, Johnson AJ. McCARTY WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients.","journal-title":"J Clin Invest"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/159779a0","volume":"159","author":"MacFarlane R.G.","year":"1947","unstructured":"MacFarlane RG, Pilling J. Fibrinolytic activity of normal urine.","journal-title":"Nature"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/jama.1958.02990310011002","volume":"167","author":"Sussman B.J.","year":"1958","unstructured":"Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion.","journal-title":"J Am Med Assoc"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.13.11.927","volume":"13","author":"Meyer J.S.","year":"1963","unstructured":"Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion.","journal-title":"Neurology"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.STR.7.2.135","volume":"7","author":"Fletcher A.P.","year":"1976","unstructured":"Fletcher AP, Alkjaersig N, Lewis M. A pilot study of urokinase therapy in cerebral infarction.","journal-title":"Stroke"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/000331978603700702","volume":"37","author":"Fujishima M.","year":"1986","unstructured":"Fujishima M, Omae T, Tanaka K, Iino K, Matsuo O, Mihara H. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction.","journal-title":"Angiology"},{"key":"ref=55","first-page":"318","volume":"34","author":"Sikri N.","year":"2007","unstructured":"Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction.","journal-title":"Tex Heart Inst J"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.58.4.485","volume":"58","author":"Tillett W.S.","year":"1933","unstructured":"Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci.","journal-title":"J Exp Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1160\/TH04-11-0724","volume":"93","author":"Collen D.","year":"2005","unstructured":"Collen D, Lijnen HR. Thrombolytic agents.","journal-title":"Thromb Haemost"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.60.2.239","volume":"60","author":"Garner R.L.","year":"1934","unstructured":"Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin.","journal-title":"J Exp Med"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.1964.03070050039011","volume":"189","author":"Meyer J.S.","year":"1964","unstructured":"Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke.","journal-title":"JAMA"},{"key":"ref=60","first-page":"349","volume":"2","author":"","year":"1988","unstructured":". Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.","journal-title":"Lancet"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","volume":"346","author":"","year":"1995","unstructured":". Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.","journal-title":"Lancet"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM199607183350301","volume":"335","author":"Hommel M.","year":"1996","unstructured":"Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke.","journal-title":"N Engl J Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14728222.12.2.159","volume":"12","author":"Gravanis I.","year":"2008","unstructured":"Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke.","journal-title":"Expert Opin Ther Targets"},{"key":"ref=64"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1016\/S0021-9258(19)69095-2","volume":"256","author":"Rijken D.C.","year":"1981","unstructured":"Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.","journal-title":"J Biol Chem"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1538-7933.2004.00645.x","volume":"2","author":"Collen D.","year":"2004","unstructured":"Collen D, Lijnen HR. Tissue-type plasminogen activator: A historical perspective and personal account.","journal-title":"J Thromb Haemost"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM198403083101001","volume":"310","author":"Van de Werf F.","year":"1984","unstructured":"Van de Werf F, Ludbrook PA, Bergmann SR. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.CIR.69.3.605","volume":"69","author":"Van de Werf F.","year":"1984","unstructured":"Van de Werf F, Bergmann SR, Fox KA. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.","journal-title":"Circulation"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2007-1002675","volume":"16","author":"Terashi A.","year":"1990","unstructured":"Terashi A, Kobayashi Y, Katayama Y, Inamura K, Kazama M, Abe T. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis.","journal-title":"Semin Thromb Hemost"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"","year":"1995","unstructured":". Tissue plasminogen activator for acute ischemic stroke.","journal-title":"N Engl J Med"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","volume":"274","author":"Hacke W.","year":"1995","unstructured":"Hacke W, Kaste M, Fieschi C. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke.","journal-title":"JAMA"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","volume":"352","author":"Hacke W.","year":"1998","unstructured":"Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).","journal-title":"Lancet"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"Hacke W.","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.","journal-title":"N Engl J Med"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","volume":"282","author":"Clark W.M.","year":"1999","unstructured":"Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.","journal-title":"JAMA"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.STR.31.4.811","volume":"31","author":"Clark W.M.","year":"2000","unstructured":"Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.","journal-title":"Stroke"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","volume":"7","author":"Davis S.M.","year":"2008","unstructured":"Davis SM, Donnan GA, Parsons MW. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial.","journal-title":"Lancet Neurol"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/STROKEAHA.116.015455","volume":"48","author":"Mill\u00e1n M.","year":"2017","unstructured":"Mill\u00e1n M, Remollo S, Quesada H. Vessel patency at 24 hours and its relationship with clinical outcomes and infarct volume in REVASCAT trial (randomized trial of revascularization with Solitaire FR device best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight hours of symptom onset).","journal-title":"Stroke"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/STROKEAHA.115.012424","volume":"47","author":"Al-Ajlan F.S.","year":"2016","unstructured":"Al-Ajlan FS, Goyal M, Demchuk AM. Intra-arterial therapy and post-treatment infarct volumes. Insights from the ESCAPE randomized controlled trial.","journal-title":"Stroke"},{"key":"ref=79","author":"","year":"2012","unstructured":". IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.","journal-title":"Lancet"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","volume":"41","author":"Tanswell P.","year":"2002","unstructured":"Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.","journal-title":"Clin Pharmacokinet"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/01.STR.0000147963.68238.da","volume":"35","author":"Zhang L.","year":"2004","unstructured":"Zhang L, Zhang ZG, Zhang C, Zhang RL, Chopp M. Intravenous administration of a GPIIb\/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.","journal-title":"Stroke"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","volume":"41","author":"Haley E.C.","year":"2010","unstructured":"Haley EC, Thompson JL, Grotta JC. Phase IIB\/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.","journal-title":"Stroke"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","volume":"366","author":"Parsons M.","year":"2012","unstructured":"Parsons M, Spratt N, Bivard A. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","volume":"14","author":"Huang X.","year":"2015","unstructured":"Huang X, Cheripelli BK, Lloyd SM. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): A phase 2, randomised, open-label, blinded endpoint study.","journal-title":"Lancet Neurol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1747493016641112","volume":"11","author":"Huang X.","year":"2016","unstructured":"Huang X, MacIsaac R, Thompson JL. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.","journal-title":"Int J Stroke"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","volume":"16","author":"Logallo N.","year":"2017","unstructured":"Logallo N, Novotny V, Assmus J. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial.","journal-title":"Lancet Neurol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","volume":"378","author":"Campbell B.C.V.","year":"2018","unstructured":"Campbell BCV, Mitchell PJ, Churilov L. Tenecteplase versus alteplase before thrombectomy for ischemic stroke.","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1476-5381.2011.01514.x","volume":"165","author":"Medcalf R.L.","year":"2012","unstructured":"Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke.","journal-title":"Br J Pharmacol"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/01.STR.0000166050.84056.48","volume":"36","author":"Reddrop C.","year":"2005","unstructured":"Reddrop C, Moldrich RX, Beart PM. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.","journal-title":"Stroke"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2011-07-369512","volume":"119","author":"Niego B.","year":"2012","unstructured":"Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.","journal-title":"Blood"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1161\/STROKEAHA.115.009917","volume":"46","author":"Mori E.","year":"2015","unstructured":"Mori E, Minematsu K, Nakagawara J. Safety and tolerability of desmoteplase within 3 to 9\u2009hours after symptoms onset in Japanese patients with ischemic stroke.","journal-title":"Stroke"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(15)00047-2","volume":"14","author":"Albers G.W.","year":"2015","unstructured":"Albers GW, von Kummer R, Truelsen T. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): A double-blind, randomised, placebo-controlled phase 3 trial.","journal-title":"Lancet Neurol"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(08)70267-9","volume":"8","author":"Hacke W.","year":"2009","unstructured":"Hacke W, Furlan AJ, Al-Rawi Y. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study.","journal-title":"Lancet Neurol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.STR.0000217403.66996.6d","volume":"37","author":"Furlan A.J.","year":"2006","unstructured":"Furlan AJ, Eyding D, Albers GW. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.","journal-title":"Stroke"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.0000149938.08731.2c","volume":"36","author":"Hacke W.","year":"2005","unstructured":"Hacke W, Albers G, Al-Rawi Y. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.","journal-title":"Stroke"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1161\/STROKEAHA.116.013715","volume":"47","author":"von Kummer R.","year":"2016","unstructured":"von Kummer R, Mori E, Truelsen T. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).","journal-title":"Stroke"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7164\/antibiotics.53.241","volume":"53","author":"Hu W.","year":"2000","unstructured":"Hu W, Ohyama S, Hasumi K. Activation of fibrinolysis by SMTP-7 and -8, novel staplabin analogs with a pseudosymmetric structure.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-9560-10-2","volume":"10","author":"Hu W.","year":"2012","unstructured":"Hu W, Narasaki R, Nishimura N, Hasumi K. SMTP (Stachybotrys Microspora Triprenyl Phenol) enhances clot clearance in a pulmonary embolism model in rats.","journal-title":"Thromb J"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1111\/j.1742-4658.2010.07783.x","volume":"277","author":"Hasumi K.","year":"2010","unstructured":"Hasumi K, Yamamichi S, Harada T. Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems.","journal-title":"FEBS J"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00210-010-0542-5","volume":"382","author":"Shibata K.","year":"2010","unstructured":"Shibata K, Hashimoto T, Nobe K, Hasumi K, Honda K. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1254\/jphs.10131FP","volume":"114","author":"Hashimoto T.","year":"2010","unstructured":"Hashimoto T, Shibata K, Nobe K, Hasumi K, Honda K. A novel embolic model of cerebral infarction and evaluation of SMTP-7, a novel fungal triprenyl phenol metabolite.","journal-title":"J Pharmacol Sci"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainres.2014.07.004","volume":"1578","author":"Ito A.","year":"2014","unstructured":"Ito A, Niizuma K, Shimizu H, Fujimura M, Hasumi K, Tominaga T. SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice.","journal-title":"Brain Res"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00210-011-0642-x","volume":"384","author":"Shibata K.","year":"2011","unstructured":"Shibata K, Hashimoto T, Nobe K, Hasumi K, Honda K. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/STROKEAHA.110.598359","volume":"42","author":"Miyazaki T.","year":"2011","unstructured":"Miyazaki T, Kimura Y, Ohata H. Distinct effects of tissue-type plasminogen activator and SMTP-7 on cerebrovascular inflammation following thrombolytic reperfusion.","journal-title":"Stroke"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neulet.2011.08.018","volume":"503","author":"Akamatsu Y.","year":"2011","unstructured":"Akamatsu Y, Saito A, Fujimura M. Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia\/reperfusion injury in rat brain.","journal-title":"Neurosci Lett"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1254\/jphs.14019FP","volume":"125","author":"Hashimoto T.","year":"2014","unstructured":"Hashimoto T, Shibata K, Ohata H, Hasumi K, Honda K. Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.","journal-title":"J Pharmacol Sci"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"35826","DOI":"10.1074\/jbc.M114.588087","volume":"289","author":"Matsumoto N.","year":"2014","unstructured":"Matsumoto N, Suzuki E, Ishikawa M, Shirafuji T, Hasumi K. Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.","journal-title":"J Biol Chem"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0270(00)00351-4","volume":"105","author":"Kito G.","year":"2001","unstructured":"Kito G, Nishimura A, Susumu T. Experimental thromboembolic stroke in cynomolgus monkey.","journal-title":"J Neurosci Methods"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/jcbfm.2013.191","volume":"34","author":"Sawada H.","year":"2014","unstructured":"Sawada H, Nishimura N, Suzuki E. SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: A study in rodents and primates.","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000069318","volume":"15","author":"","year":"2003","unstructured":". Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.","journal-title":"Cerebrovasc Dis"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:43:46Z","timestamp":1663119826000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170826\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190319115018","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}